Results 121 to 130 of about 10,632 (179)
Some of the next articles are maybe not open access.
Drugs of Today, 2007
Darunavir is a nonpeptidic protease inhibitor recently approved for the treatment of antiretroviral therapy-experienced patients. It has potent in vitro activity against viral isolates that are resistant to currently licensed protease inhibitors. In randomized clinical trials with optimized background regimens, it has shown virologic and immunologic ...
Wissam I, El-Atrouni, Zelalem, Temesgen
openaire +4 more sources
Darunavir is a nonpeptidic protease inhibitor recently approved for the treatment of antiretroviral therapy-experienced patients. It has potent in vitro activity against viral isolates that are resistant to currently licensed protease inhibitors. In randomized clinical trials with optimized background regimens, it has shown virologic and immunologic ...
Wissam I, El-Atrouni, Zelalem, Temesgen
openaire +4 more sources
Pharmacoeconomics of darunavir
Expert Review of Pharmacoeconomics & Outcomes Research, 2011Darunavir boosted with ritonavir (DRV/r) in combination with other antiretrovirals (ARVs) was initially approved in 2006 for the treatment of HIV infection in ARV treatment-experienced adults and has subsequently been approved for use in treatment-naive adults in 2008.
Dwight S, Fullerton +3 more
openaire +2 more sources
Darunavir: A comprehensive profile
2021Darunavir: (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl [(2S,3R)-4-{[(4-aminophenyl)sulfonyl] (isobutyl)amino}-3-hydroxy-1-phenyl-2-butanyl]carbamate is a synthetic non-peptide protease inhibitor. On June 2006, it was first approved by the Food and Drug administration (FDA) for treatment of resistant type-1 of the human immunodeficiency virus (HIV).
Ibrahim A, Darwish +5 more
openaire +2 more sources
Clinical Pharmacokinetics of Darunavir
Clinical Pharmacokinetics, 2007Darunavir (TMC114) is a newly developed HIV-1 protease inhibitor with potent antiviral activity against both wild-type and multidrug resistant HIV-1 strains. The drug is currently approved by the US FDA for antiretroviral treatment-experienced patients with limited therapeutic options.
Michael, Rittweger, Keikawus, Arastéh
openaire +2 more sources
Enfermedades Infecciosas y Microbiología Clínica, 2008
The resistance profile of darunavir (DRV) was initially explored using pooled week 24 data from POWER 1, 2, and 3 at the recommended dose of DRV (n=467) with the subsequent addition of data from the placebo arm without etravirine (ETR) of DUET 1 and 2 (n=604).
openaire +1 more source
The resistance profile of darunavir (DRV) was initially explored using pooled week 24 data from POWER 1, 2, and 3 at the recommended dose of DRV (n=467) with the subsequent addition of data from the placebo arm without etravirine (ETR) of DUET 1 and 2 (n=604).
openaire +1 more source